ACT Genomics is Collaborating With Ignyta on Phase II STARTRK-2 Trial of Entrectinib

2017-01-26

ACT Genomics has entered into a service agreement to screen patients for Ignyta, an oncology biotechnology company, who is enrolling all types of solid tumor patients harboring NTRK1,2,3/ROS1/ALK gene fusions into the phase II STARTRK-2 trial of entrectinib. ACT Genomics is the selected vendor in Taiwan to provide screening service in its CAP-accredited laboratory.


More info about Ignyta: https://ignyta.com/

日韩av电影,色YEYE高清在线视频,欧美XXZOZO,JAPANESE 18日本护士